In vitro percutaneous absorption enhancement of granisetron by chemical penetration enhancers
- 19 March 2012
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 39 (4) , 561-568
Abstract
Granisetron (GRN), a potent antiemetic agent, is frequently used to prevent nausea and vomiting induced by cancer cytotoxic chemotherapy and radiation therapy. Objective: As part of our efforts to further modify the physicochemical properties of this market drug, with the ultimate goal to formulate a better dosage form for GRN, this work was carried out to improve its permeability in vitro. Methods: The permeation behavior of GRN in isopropyl myristate (IPM) was investigated across excised rabbit abdominal skin and the enhancing activities of three novel O-acylmenthol derivatives synthesized in our laboratory as well as five well-known chemical enhancers were evaluated. Results: It was found that the steady-state flux of granisetron free base (GRN-B) was about 26-fold higher than that of granisetron hydrochloride (GRN-H). The novel enhancer, 2-isopropyl-5-methylcyclohexyl heptanoate (M-HEP), was observed to provide the most significant enhancement for the absorption of GRN-B. When incorporated in the donor solution with the optimal enhancer M-HEP, the steady-state flux of GRN-B increased from (196.44 ± 12.03) μg·cm−2·h−1 to (1044.95 ± 71.99) μg·cm−2·h−1 (P < 0.01). Conclusion: These findings indicated that the application of chemical enhancers was an effective approach to increase the percutaneous absorption of GRN in vitro.Keywords
This publication has 42 references indexed in Scilit:
- A statistical approach to the development of a transdermal delivery system for ondansetronInternational Journal of Pharmaceutics, 2010
- Dermal, Subdermal, and Systemic Concentrations of Granisetron by Iontophoretic DeliveryPharmaceutical Research, 2005
- The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using ratsEnvironmental Toxicology and Pharmacology, 2005
- Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysisSupportive Care in Cancer, 2004
- Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupportive Care in Cancer, 2004
- Granisetron: An Update on its Clinical Use in the Management of Nausea and VomitingThe Oncologist, 2004
- Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomitingCancer, 2000
- Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 1999
- An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomitingEuropean Journal of Cancer, 1997
- Percutaneous Absorption of DrugsClinical Pharmacokinetics, 1992